Literature DB >> 17022298

Dental management of chemoradiation patients.

Evelyn M Chung1, Eric C Sung.   

Abstract

The utilization of combined chemoradiation therapy has recently increased in the treatment of head and neck cancers. This patient population is significantly more prone to various oral complications during and after medical therapy. Oral complications and long-term effects include mucositis, xerostomia, alterations in taste, vascular compromise, mucosal thinning and increased risk of rampant caries and periodontal disease. The most serious oral complication that can arise is osteoradionecrosis. Managing patients properly prior to medical treatment can help decrease these potential complications during and after treatment. This purpose of this article is to review the different radiation and chemotherapy regimens used to treat patients with head and neck cancers, as well as protocols in the dental management of these patients before, during, and after medical treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17022298

Source DB:  PubMed          Journal:  J Calif Dent Assoc        ISSN: 1043-2256


  3 in total

1.  Comparison of different criteria for periodontitis case definition in head and neck cancer individuals.

Authors:  Audrey Cristina Bueno; Raquel Conceição Ferreira; Luis Otávio Miranda Cota; Guilherme Carvalho Silva; Cláudia Silami Magalhães; Allyson Nogueira Moreira
Journal:  Support Care Cancer       Date:  2015-01-25       Impact factor: 3.603

2.  Awareness about oral cancer among dental postgraduate students in the State of Andhra Pradesh, India.

Authors:  P Ramaswamy; Ginjupally Uday; P Sreenivasulu; B Praveen Kumar; Tanya Khaitan; V R Geethika
Journal:  J Cancer Educ       Date:  2014-12       Impact factor: 2.037

Review 3.  Oral health of adult patients undergoing hematopoietic cell transplantation. Pre-transplant assessment and care.

Authors:  Agnieszka Bogusławska-Kapała; Kazimierz Hałaburda; Ewa Rusyan; Hubert Gołąbek; Izabela Strużycka
Journal:  Ann Hematol       Date:  2017-02-13       Impact factor: 3.673

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.